The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

EDP-323 is an investigational inhibitor of Respiratory Syncytial Virus (RSV), currently showing promising results in Phase 2a ...

Namibia has made significant strides in stemming the spread of HIV and AIDS through education and prevention. However, for ...

The World Council of Churches has newly published a discussion document: Good News about HIV Treatment, Cure, and Healing: ...

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...

New data from the PURPOSE 2 trial continue to show the efficacy of lenacapavir in HIV prevention in individuals who have sex ...

From oral PrEP, to injectables, rings, and implants, this year's HIV Research for Prevention conference was all about options ...

Uganda's efforts to combat the HIV/AIDS epidemic have made significant strides, yet crucial gaps remain, particularly in preventing mother-to-child transmission of the virus.

Clarence Peeples is part of a small club in the HIV community. He is using his experiences to help fight the virus among ...

Two posters compared health care resource utilization (HCRU) and financial burdens of people living with HIV with a non-HIV ...

The availability of such kidney transplants outside of the research setting could substantially improve organ availability ...